

# Program Announcement

for the

Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

## Gulf War Illness Research Program

### Gulf War Illness Epidemiology Research Award

**Funding Opportunity Number: W81XWH-15-GWIRP-GWIERA**

**Catalog of Federal Domestic Assistance Number: 12.420**

#### SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Deadline:** 5:00 p.m. Eastern time (ET), August 13, 2015
- **Invitation to Submit an Application:** September 2015
- **Application Submission Deadline:** 11:59 p.m. ET, October 29, 2015
- **End of Application Verification Period:** 5:00 p.m. ET, November 3, 2015
- **Peer Review:** January 2016
- **Programmatic Review:** March 2016

*The CDMRP eReceipt System has been replaced with the electronic Biomedical Research Application Portal (eBRAP). Principal Investigators and organizational representatives should register in eBRAP as soon as possible. All pre-applications must be submitted through eBRAP. In addition, applications submitted through Grants.gov will now be available for viewing, modification, and verification in eBRAP prior to the end of the application verification period.*

*This Program Announcement/Funding Opportunity is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.*

## TABLE OF CONTENTS

<b>I. Funding Opportunity Description.....</b>	<b>3</b>
A. Program Description .....	3
B. Award Information.....	3
C. Eligibility Information .....	6
D. Funding .....	6
<b>II. Submission Information .....</b>	<b>7</b>
A. Where to Obtain the Grants.gov Application Package .....	8
B. Pre-Application Submission Content.....	8
C. Full Application Submission Content.....	11
D. Applicant Verification of Grants.gov Submission in eBRAP .....	18
E. Submission Dates and Times .....	19
F. Other Submission Requirements.....	19
<b>III. Application Review Information .....</b>	<b>19</b>
A. Application Review and Selection Process.....	19
B. Application Review Process .....	20
C. Recipient Qualification .....	22
D. Application Review Dates .....	22
E. Notification of Application Review Results .....	22
<b>IV. Administrative Actions.....</b>	<b>22</b>
A. Rejection .....	22
B. Modification.....	23
C. Withdrawal.....	23
D. Withhold .....	23
<b>V. Award Administration Information.....</b>	<b>24</b>
A. Award Notice .....	24
B. Administrative Requirements .....	24
C. National Policy Requirements .....	24
D. Reporting.....	24
E. Award Transfers.....	24
<b>VI. Agency Contacts.....</b>	<b>25</b>
A. CDMRP Help Desk.....	25
B. Grants.gov Contact Center.....	25
<b>VII. Application Submission Checklist.....</b>	<b>26</b>

## **I. FUNDING OPPORTUNITY DESCRIPTION**

### **A. Program Description**

Applications to the Fiscal Year 2015 (FY15) Gulf War Illness Research Program (GWIRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The GWIRP was initiated in 2006 to provide support for research of exceptional scientific merit to study the health effects of deployment to the 1990-1991 Persian Gulf War on U.S. Warfighters. Appropriations for the GWIRP from FY06 through FY14 have totaled \$89 million (M). The FY15 appropriation is \$20M.

The GWIRP challenges the scientific community to design high-impact research that will improve the health and lives of Veterans who have Gulf War illness (GWI). GWI is characterized by multiple diverse symptoms that typically include chronic headache, widespread pain, cognitive difficulties, debilitating fatigue, gastrointestinal problems, respiratory symptoms, sleep problems, and other abnormalities that are not explained by established medical diagnoses or standard laboratory tests.

The population of Veterans affected by GWI is a subset of the nearly 700,000 who served during the Gulf War. Specifically, these Gulf War Veterans were deployed to the theatre of operations in Southwest Asia, including Iraq, Kuwait, and Saudi Arabia. Studies indicate that approximately 25% to 30% (or 175,000 to 210,000) of Gulf War Veterans continue to experience symptoms associated with their deployment as described above.

The GWIRP has a dual focus for its FY15 funding. As in past years, the GWIRP will focus on innovative projects that have the potential to make a significant impact on finding treatments for GWI. For FY15, the GWIRP includes an additional focus on studies to characterize patterns of health and disease in Gulf War Veterans.

### **B. Award Information**

The Gulf War Illness Epidemiology Research Award mechanism is being offered for the first time in FY15.

The purpose of this award is to support population-based research to obtain a better understanding of mortality, morbidity, and symptomatology over time in Veterans deployed in the 1990-1991 Persian Gulf War and afflicted by GWI. While individual symptoms experienced by ill Gulf War Veterans can vary from person to person, the types of symptoms reported are comparable and typically include some combination of widespread pain and headaches, fatigue, cognitive impairment, gastrointestinal symptoms, and skin abnormalities. GWI case definitions published to date may be improved through the consideration of additional epidemiological data describing symptom onset, duration, severity, and laboratory findings. The Gulf War Illness Epidemiology Research Award will support hypothesis-driven or discovery-based research into

mortality, morbidity, and symptomatology and/or how these have changed or progressed over time in the Gulf War Veteran population compared to rates and patterns of change with time in appropriate control populations.

Topic areas of interest under the Gulf War Illness Epidemiology Research Award include but are not limited to:

- Mortality (rate and causes)
- Descriptors of symptomatology (e.g., duration, frequency, severity, etc.) and changes to those associated with GWI
- Clinical diagnoses and laboratory findings
- Symptom clustering and subgrouping
- Gender and racial differences

The April 2014 report of the Research Advisory Committee on Gulf War Veterans' Illnesses (available online at <http://www.bu.edu/sph/files/2014/04/RAC2014.pdf>) notes that Gulf War Veterans exposed to nerve gas release and oil well fires have elevated rates of death due to brain cancer. However "very little other research has yet been conducted to determine rates at which Gulf War Veterans have been affected by other medical conditions of possible concern, including neurological diseases such as multiple sclerosis or Parkinson's disease, other cancers, sleep disorders, adverse pregnancy outcomes or rates of birth defects in Veterans' children." Therefore, studies proposed under this award may also address questions related to medical conditions co-occurring with GWI or related to Gulf War Veteran offspring; however, the primary focus of the study must be epidemiological characterization of the Gulf War Veteran population.

The GWIRP intends to fund studies that address broad populations, or comparative populations that can inform one or more of the topic areas listed above. Studies that address small populations, populations associated with very limited catchment, specific military units or geographic areas of deployment, or limited sets of symptoms, markers, or effects must be well justified as to why the scope has been specifically limited. Revisiting previously studied cohorts to generate or extend longitudinal data is one example of a reasonable justification.

PIs must provide documentation of the availability of and access to a suitable Gulf War Veteran population that will support a meaningful outcome for the study and discuss how accrual goals will be achieved and how standards of care may impact the study population. PIs are encouraged to collaborate with an investigator who has demonstrated access to a broad population of Gulf War Veterans, particularly investigators within the U.S. Department of Veterans Affairs (VA).

The application should include a clearly articulated statistical analysis plan including statistical expertise and a power analysis reflecting sample size projections that will clearly answer the objectives of the study. The application must also include a data management plan and use of an appropriate database to safeguard and maintain the integrity of the data. Applicants proposing to collect human anatomical substances for laboratory study are encouraged to correlate samples analyses to medical/administrative records gathered or generated in the study.

***This award may not be used to conduct clinical trials, research focused on amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease), or studies whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI.***

***GWI Case Definitions:*** In 2014, the Institute of Medicine (IOM) released the report “Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined” (available online at <http://www.iom.edu/Reports/2014/Chronic-Multisymptom-Illness-in-Gulf-War-Veterans-Case-Definitions-Reexamined.aspx>). In this report, the IOM recommends the use of both, the Centers for Disease Control and Prevention (CDC) definition of GWI and the Kansas definition for GWI. Therefore, applicants proposing clinical research may construct a definition of subgroups or symptom clusters as appropriate to the specific research; however, all cases and controls must additionally be scored and analyzed according to both the CDC and the Kansas definitions of GWI for comparative purposes. Any project-specific case definition must recognize the multisymptom nature of GWI.

Note: The 2014 report of the Research Advisory Committee on Gulf War Veterans’ Illnesses, “Gulf War Illness and the Health of Gulf War Veterans: Research Update and Recommendations, 2009-2013,” provides information on GWI, including case definitions and research on epidemiology, etiology, pathobiology, and treatment. This 2014 report can be found online at <http://www.bu.edu/sph/files/2014/04/RAC2014.pdf>.

***Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this Program Announcement/Funding Opportunity.*** For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided in the electronic Biomedical Research Application Portal (eBRAP) at <https://ebrap.org/eBRAP/public/Program>. Principal Investigators (PIs) seeking funding for a clinical trial should consider submitting an application for the FY15 GWIRP Innovative Treatment Evaluation Award (W81XWH-15-GWIRP-ITEA) or Clinical Trial Award (W81XWH-15-GWIRP-CTA).

**Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers:** All Department of Defense (DoD)-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to the local Institutional Review Board (IRB) of record. Local IRB approval at the time of submission is ***not*** required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB. ***Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes.*** Refer to the General Application Instructions, Appendix 5, and the Human Subject Resource Document available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) for additional information.

***The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the***

*research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 3, Section L.*

### **C. Eligibility Information**

- Independent investigators at all academic levels (or equivalent) are eligible to apply.
- Cost sharing/matching is not an eligibility requirement.
- Eligible investigators must apply through an organization. Organizations eligible to apply include national, international, for-profit, nonprofit, public, and private organizations.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

### **D. Funding**

- The maximum period of performance is **4** years.
- The anticipated direct costs budgeted for the entire period of performance will not exceed **\$975,000**. Associated indirect costs can be budgeted in accordance with the organization's negotiated rate. No budget will be approved by the Government exceeding **\$975,000** direct costs or using an indirect rate exceeding the organization's negotiated rate.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

Refer to the General Application Instructions, Section II.C.5., for budget regulations and instructions for the Research & Related Budget. ***For all Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in Section II.C.5. of the General Application Instructions.***

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI(s) to disseminate project results at one DoD military-relevant meeting. For planning purposes, it should be assumed that the meeting will be held in the National Capital Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Salary
- Research-related subject costs
- Clinical research costs
- Veteran subject reimbursement and compensation

- Support for multidisciplinary collaborations
- Travel between collaborating organizations
- Travel costs to attend scientific/technical meetings in addition to the required meeting described above

Intramural (DoD), other Federal agency, and extramural investigators are encouraged to apply to this Program Announcement/Funding Opportunity. An intramural investigator is defined as a DoD military or civilian employee working within a DoD laboratory or medical treatment facility, or working in a DoD activity embedded within a civilian medical center. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective resource managers. It is permissible for an intramural investigator to be named as a collaborator on an application submitted by an extramural investigator. ***In such cases, the extramural investigator must include a letter from the intramural collaborator's Commander or Commanding Officer that authorizes the involvement of the intramural collaborator.***

As required of all applicants to this Program Announcement/Funding Opportunity, if PIs from Federal agencies submit applications, they must submit through Grants.gov. Therefore, Federal applicants must be familiar with Grants.gov requirements, including the need for an active System for Award Management (SAM) registration and a Data Universal Numbering System (DUNS) number. Refer to Section II.A. of the General Application Instructions for further information regarding Grants.gov requirements.

Awards to extramural organizations will consist solely of assistance agreements (Cooperative Agreements and Grants). Awards to intramural agencies and other Federal agencies may be executed through a direct fund transfer (e.g., the Military Interdepartmental Purchase Request [MIPR] or Funding Authorization Document [FAD] process). Direct transfer of funds from the recipient to a Federal agency is not allowed except under very limited circumstances. Refer to the General Application Instructions, Section II.C.5. Research & Related Budget, for additional information on budget considerations for applications involving Federal agencies.

***The CDMRP expects to allot approximately \$1.6M of the \$20M FY15 GWIRP appropriation to fund approximately one Gulf War Illness Epidemiology Research Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.***

## **II. SUBMISSION INFORMATION**

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

Submission is a two-step process requiring both (1) pre-application submission through the electronic Biomedical Research Application Portal (eBRAP) (<https://eBRAP.org/>) and (2) application submission through Grants.gov (<http://www.grants.gov/>). Refer to the General

Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov.

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization's representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant's responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

PIs should ensure that their name and email address are the same as the name and email address that will be provided on the SF-424 Form of the Grants.gov application package submitted to Grants.gov. The organization, Business Officials, PI(s), and eBRAP log number named in the full application submitted to Grants.gov must match those named in the pre-application in eBRAP.

***Application viewing, modification, and verification in eBRAP is strongly recommended, but not required. The Project Narrative and Budget cannot be changed after the application submission deadline. Any other application component cannot be changed after the end of the application verification period.***

#### **A. Where to Obtain the Grants.gov Application Package**

To obtain the Grants.gov application package, including all required forms, perform a basic search using the Funding Opportunity Number W81XWH-15-GWIRP-GWIERA in Grants.gov (<http://www.grants.gov/>).

#### **B. Pre-Application Submission Content**

All pre-application components must be submitted by the PI through eBRAP (<https://eBRAP.org/>). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Application Information – Tab 1**

- **Application Contacts – Tab 2**

- Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application,” in Block 5 of the Grants.gov SF-424 form). The Business Official must either be selected from the eBRAP list or invited in order for the pre-application to be submitted.
- It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Collaborators and Key Personnel – Tab 3**

- Enter the name, organization, and role of all collaborators and key personnel associated with the application.
- Applicants with little experience in research involving Veterans with GWI are strongly encouraged to include at least one collaborator having such experience from the early planning stages onward.
- FY15 GWIRP Integration Panel (IP) members should not be involved in any pre-application or application. For questions related to IP members and pre-applications or applications, refer to [Section IV.C., Withdrawal](#), or contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

- **Conflicts of Interest (COIs) – Tab 4**

- List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Pre-Application Files – Tab 5**

*Note: Upload document(s) as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

**Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Research Idea:** State the population-based topic area(s) directly relevant to GWI that will be addressed. State the ideas and reasoning on which the proposed work is based and why the study should be conducted, given the current state of knowledge.
- **Research Strategy:** Concisely state the project’s objectives and specific aims. If the study will use a case definition in addition to the CDC and Kansas definitions, describe it briefly and summarize the rationale.

- **Impact:** State how the improved understanding of patterns of illness and health obtained with this award would advance our understanding of GWI, would improve clinical treatment of Gulf War Veterans with GWI, would improve the definition and diagnosis of GWI, or would otherwise advance the state of GWI treatment or research.
- **Personnel:** Briefly state the qualifications of the PI and expertise of key personnel to perform the described research project.

**Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application *must be uploaded as individual documents* and are limited to:

- References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
- Key Personnel Biographical Sketches (five-page limit per individual).
- **Submit Pre-Application – Tab 6**
  - This tab must be completed for the pre-application to be accepted and processed.

## Pre-Application Screening

- **Pre-Application Screening Criteria**

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the GWIRP, pre-applications will be screened based on the following criteria:

- **Research Idea:** Whether the Preproposal Narrative addresses a population-based topic area(s) directly relevant to GWI. Whether the described research focuses specifically on Veterans with GWI and how the rationale supports the proposed research.
- **Research Strategy:** Whether the specific aims and objectives support the research idea. If applicable, the extent to which a case definition(s) other than the CDC or Kansas definition is appropriate to the study.
- **Impact:** Whether the proposed research will generate population-based data that will improve our understanding of GWI, and make a short-term or long-term improvement in clinical treatment of Veterans with GWI, or the definition and diagnosis of GWI.
- **Personnel:** Whether the qualifications of the PI and key personnel are appropriate to perform the proposed research project. For PIs with little or no GWI experience, how the PI has integrated a collaborator(s) with GWI expertise onto the research team.

- **Notification of Pre-Application Screening Results**

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the [title page](#) of this Program Announcement/Funding Opportunity.

### C. Full Application Submission Content

*Applications will not be accepted unless the PI has received notification of invitation.*

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed Grants.gov application package provided in Grants.gov for this Program Announcement/Funding Opportunity. The Grants.gov application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (<http://www.grants.gov/>).

**Note: The Project Narrative and Budget Form cannot be changed after the application submission deadline.** If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or Budget Form needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID *prior to the application submission deadline*.

**Grants.gov application package components:** For the Gulf War Illness Epidemiology Research Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. **SF-424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

2. **Attachments Form**

Each attachment to the Grants.gov application forms must be uploaded as an individual PDF file in accordance with the formatting guidelines listed in Appendix 2 of the General Application Instructions. For all attachments, ensure that the file names are consistent with the guidance. Grants.gov will reject attachments with file names longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, Grants.gov has file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire Grants.gov application package may not exceed 200 MB.

- **Attachment 1: Project Narrative (12-page limit): Upload as “ProjectNarrative.pdf.”** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams,

chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below. The Project Narrative may include preliminary data relevant to GWI and the proposed project, but these data are not required to have come from GWI research. Applications not supported by preliminary data should be based on sound scientific rationale.

- **Background:** State which population-based topic area directly relevant to GWI that will be addressed. Present the ideas and reasoning behind the proposed work and why the study should be conducted, given the current state of knowledge. Cite relevant literature.
- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be achieved. Both hypothesis-driven and discovery-based studies are allowed.
- **Specific Aims:** Concisely explain the project’s specific aims to be funded by this application. If the proposed work is part of a larger study, present only tasks that this award will fund.
- **Research Strategy:** Describe the study design, methods, and analyses, including appropriate controls. If applicable, describe validation against existing datasets. Address potential problem areas and present alternative methods and approaches.
  - All subjects and controls must be scored at least according to both CDC and Kansas case definitions for GWI for the purpose of comparative analysis. If any additional case definition other than the CDC or Kansas definition is to be used, describe this definition and explain the rationale behind its inception and use. Describe any subgrouping or clustering to be used and explain the significance of each. Any case definition must recognize the multisymptom nature of GWI.
  - If using psychometric measures, describe their reliability and validity.
- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. ***There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested will result in the removal of those items or may result in administrative withdrawal of the application.***
  - **References Cited:** List the references cited (including URLs if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
  - **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.
- Publications and/or Patent Abstracts: Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement/Funding Opportunity, such as those from members of Congress, do not impact application review or funding decisions.
- Letters of Collaboration: Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. Applicants with little or no experience in research involving Veterans with GWI are strongly encouraged to collaborate with ~~other~~ researchers that have Gulf War illness expertise
- Intellectual Property
  - Background and Proprietary Information: All software and data first produced under the award are subject to a Federal purpose license. Provide a list of all background intellectual property to be used in the project or provide a statement that none will be used. If applicable, state and identify the proprietary information that will be provided to the Government and indicate whether the applicant will require a waiver of the Federal purpose license.
  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
- Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 3, Section L for more information about the CDMRP expectations for making data and research resources publicly available.
- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf.”** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

The technical abstract is used by all reviewers. The programmatic reviewers may not have access to the full application and may rely on the technical abstract for appropriate description of the project's key aspects. Therefore, clarity and completeness within the space limits of the technical abstract are highly important.

Technical abstracts should be structured as follows:

- Background: State the topic area to be addressed and present the ideas and reasoning behind the proposed work.
  - Objective/Hypothesis: State the central hypothesis or objective of the project.
  - Specific Aims: State the specific aims of the study.
  - Study Design: Briefly describe the study design including the subject population, controls, subgroups and any extraordinary case definitions to be used if important to the study purposes.
  - Impact: Briefly describe how the proposed project will have an impact on veterans with GWI, our understanding of the natural history of GWI and future GWI research.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf.”** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. *Do not duplicate the technical abstract.* Minimize use of acronyms and abbreviations. The lay abstract is an important component of the application review process because it outlines issues of particular interest to the consumer advocate community.

- Clearly describe the scientific objective and rationale for the proposed project in a manner that will be readily understood by readers without scientific or medical backgrounds. Indicate the topic area being addressed.
  - Describe the ultimate applicability and impact of the research.
    - Describe the subject and control population being proposed.
    - Explain how this study will inform the diagnosis or care of the population of Gulf War Veterans with GWI.
    - Describe the likely contributions of this study to advancing our understanding of GWI.
    - How this study will help inform future GWI research.
- **Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf.”** The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>). For the Gulf War Illness Epidemiology Research Award mechanism, use the SOW format example titled “SOW for Clinical Research.” The SOW must be in PDF format prior to attaching.

Refer to the General Application Instructions, Section II.C.3., for detailed guidance on creating the SOW.

The GWIRP strongly encourages timely dissemination of the results of GWIRP-sponsored research as a product of the research program. Timely dissemination is critical to improvement of the lives of veterans with GWI, the advancement of the field, and the continued success of the program. Therefore, SOWs submitted to the GWIRP must include at least one task or aim focused on preparation and submission of publications. This task or aim must be scheduled to commence at least six months prior to the end of the award's period of performance.

- **Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf.”**  
Explain how the project addresses a critical problem in GWI. Describe how the outcomes of the project will advance the GWI treatment or research by improving our understanding of mortality, morbidity, and symptomatology, improving the definition and diagnosis of GWI, improving the treatment of Veterans with GWI, or other outcomes.
- **Attachment 7: Human Subject and Statistical Plan (two-page limit): Upload as “SubjectPlan.pdf.”**
  - Include a detailed plan for the recruitment of Gulf War Veterans or the acquisition of samples and/or data. Specifically demonstrate plans to access Veterans and or obtain personal data on Veterans. If applicable, describe any existing datasets to be used and how they will be gathered or accessed. Address potential problem areas and present alternative methods and approaches. If applicable, outline past recruitment strategies and successes in recruiting similar populations.
  - Describe how the proposed study population is appropriate to study the hypotheses. Include potential issues regarding ethics, information privacy, and assessment of risk versus benefit of participation, and other regulatory considerations.
  - Describe the availability of this population, whether the PI and/or research team currently have access to this population, and how access to potential participants/tissues/data will be coordinated. If applicable, provide a letter(s) from an appropriate authority showing approved access to Gulf War Veterans or use of data from Veterans (e.g., Defense Manpower Data Center Data Request System, collaborating investigator(s) from the Department of Veterans Affairs, etc.), if applicable. PIs whose applications will require obtaining and/or using Veterans' data from VA or military databases should confirm the ability to meet database requirements prior to application submission. A letter of support, signed by the lowest-ranking person with approval authority, should be included for studies involving Veterans, VA- or military-controlled study materials, and/or VA or military databases.
  - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study. Note: PIs are urged to consider including reimbursement for travel and

accommodations and/or other appropriate expenses for participating Gulf War Veterans.

- Describe how the proposed sampling strategy is appropriate for the study hypotheses, design, methods, and analytical/statistical plans, including evidence that the study will be appropriately powered.
  - ***Inclusion of Women and Minorities in Study.*** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the clinical trial
- **Attachment 8: Data Management Plan (no page limit): Upload as “Data\_Manage.pdf.”** The Data Management attachment should include the components listed below.
    - a. **Data Management:** Describe all methods used for data collection to include the following:
      - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
      - **Confidentiality:**
        - Explain how the privacy of human subjects and the confidentiality of study data will be protected. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
        - Address who will have access to study records, data, and specimens. Include an acknowledgment that representatives of the DoD are eligible to review study records.
        - Address requirements for reporting sensitive information to state or local authorities.
      - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data.
      - **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.

**b. Laboratory Evaluations** if applicable:

- **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.
  - **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).
  - **Storage:** Describe specimen storage including location of storage, length of storage, labeling, specimen disposition, and any special conditions required. Outline the plan to store specimens for future use to include considerations for informed consent while providing human subjects an opportunity to decline participation in the study.
  - **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.
  - **Linking Samples to Other Data:** Applicants proposing to collect human anatomical substances for laboratory study are encouraged to correlate sample analyses to survey and medical/administrative records gathered or generated in the study.
- **Attachment 9: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit):** Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments.
    - For each instrument, describe how the information collected is related to the objectives of the study
    - Describe validation of the survey instruments and how they are compatible with instruments used in past published surveys.

**Attachment 10: Outcomes Statement (one-page limit): Upload as “Outcomes.pdf.”** If applicable, list all prior research projects/awards relating to GWI, including resulting publications, abstracts, patents or other tangible outcomes. Only research and outcomes directly relevant to GWI should be listed. Note: This item will be made available for programmatic review.

**Attachment 11: Collaborating DoD Military Facility Budget Form(s), if applicable: Upload as “MFBudget.pdf.”** If a Military Facility (military health system facility, research laboratory, treatment facility, dental treatment facility, or a

DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the Collaborating DoD Military Facility Budget Form (available for download on the eBRAP “Funding Opportunities & Forms” web page), including a budget justification, for each Military Facility as instructed. Refer to the General Application Instructions, Section II.C.8., for detailed information.

3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C.4., for detailed information. Note: Some of the items in this attachment may be made available for programmatic review.
  - PI Biographical Sketch (five-page limit): Upload as “Biosketch\_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The five-page National Institutes of Health Biographical Sketch may also be used.
  - PI Previous/Current/Pending Support (no page limit): Upload as “Support\_LastName.pdf.”
  - Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch\_LastName.pdf.”
  - Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support\_LastName.pdf.”
4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C.5., for detailed information.
  - Budget Justification (no page limit): Upload as “BudgetJustification.pdf.” The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.
5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C.6., for detailed information.
6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C.7., for detailed information.

#### **D. Applicant Verification of Grants.gov Submission in eBRAP**

Prior to the end of the application verification period, PIs and organizational representatives can review and modify in eBRAP certain components of an application submitted to Grants.gov. Following retrieval and processing of the Grants.gov application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the Grants.gov application submission. eBRAP will validate retrieved files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in both the email and in the Full Application Files tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement/Funding Opportunity. ***If either the Project Narrative or the budget fails eBRAP validation, an updated Grants.gov***

*application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.* The Project Narrative and Budget Form cannot be changed after the application submission deadline.

#### **E. Submission Dates and Times**

All submission dates and times are indicated on the [title page](#) of this Program Announcement/ Funding Opportunity. Pre-application and application submissions are required. Failure to meet either of these deadlines will result in application rejection.

#### **F. Other Submission Requirements**

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Section II.A., for information on Grants.gov registration requirements.

### **III. APPLICATION REVIEW INFORMATION**

#### **A. Application Review and Selection Process**

All applicants are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the DHA RDA Directorate and the Office of the Assistant Secretary of Defense for Health Affairs, based on (a) technical merit and (b) the relevance to the mission of the DHP, the GWIRP, and to the specific intent of the award mechanism. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier process used by the CDMRP can be found at <http://cdmrp.army.mil/about/fundingprocess>.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a nondisclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.

## **B. Application Review Process**

**1. Peer Review:** To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

- **Research Strategy and Feasibility**
  - How well the hypotheses or objectives, aims, study design, methods, and analyses, are developed and integrated into the project.
  - How well developed and justified are any case definitions proposed in addition to the required CDC or Kansas case definitions.
  - How well the application demonstrates the feasibility for successful completion of the proposed study within the specified performance period using with the available resources.
  - How well the application identifies potential problems and addresses alternative approaches.
  - To what degree the data collection instruments (e.g., surveys, questionnaires), if applicable, are appropriate to the proposed study. Whether proposed data collection instruments are compatible with previous studies.
- **Impact**
  - To what extent the project will improve our understanding of mortality, morbidity, and symptomatology in the population of Veterans with GWI.
  - To what extent the improved characterization of mortality, morbidity, and symptomatology in the GWI population achieved in this study will have a significant impact on diagnosis or treatment of Veterans with GWI or will advance our understanding of GWI in general.
- **Human Subject and Statistical Plan**
  - How well the selected population is described and how well it represents the population of 1990-1991 Gulf War Veterans as a whole.
  - Whether the PI has demonstrated access to the proposed Gulf War Veteran population in numbers that will support a meaningful outcome. Whether the PI has provided a letter from an appropriate authority showing approved access to Gulf War Veterans or use of data from Veterans.
  - Whether an appropriate statistical plan, including sample size projections and power analysis, is present and adequate for the study.
  - How well the application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.
  - Whether issues regarding ethics, information privacy, and assessment of risk versus benefit of participation, and other regulatory considerations, have been adequately considered

- **Data Management Plan**
  - How well-developed and feasible is the proposed data management plan.
- **Personnel**
  - Whether the levels of effort by the PI and other key personnel are appropriate to ensure success of the project.
  - How well the PI's record of accomplishment demonstrates his/her ability to perform the proposed work.
  - How the research team's background and expertise are appropriate to accomplish the proposed work.
  - For PIs with little or no GWI experience, whether the PI has integrated a collaborator(s) with GWI expertise onto the research team.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.
- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.
- **Environment**
  - To what extent the scientific environment is appropriate for the proposed research.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - Whether the quality and extent of organizational support are appropriate for the proposed research.
  - If applicable, to what degree the intellectual and material property plan is appropriate.

**2. Programmatic Review:** To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following equally considered criteria are used by programmatic reviewers:

- a. **Ratings and evaluations of the peer reviewers**
- b. **Relevance to the mission of the DHP and FY15 GWIRP, as evidenced by the following:**

- Adherence to the intent of the award mechanism
- Program portfolio composition
- Programmatic relevance
- Relative impact
- Relative outcomes from the PIs previous GWI related research, if applicable

### **C. Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

### **D. Application Review Dates**

All application review dates and times are indicated on the [title page](#) of this Program Announcement/Funding Opportunity.

### **E. Notification of Application Review Results**

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

## **IV. ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from eBRAP or applications from Grants.gov, the following administrative actions may occur:

### **A. Rejection**

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different Funding Opportunities within the same program and fiscal year.

## **B. Modification**

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

## **C. Withdrawal**

The following may result in administrative withdrawal of the pre-application or application:

- A FY15 GWIRP Integration Panel (IP) member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY15 GWIRP IP members can be found at <http://cdmrp.army.mil/gwirp/panels/panels15>.
- The application fails to conform to this Program Announcement/Funding Opportunity description to the extent that appropriate review cannot be conducted.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
- The invited application does not propose the same research project described in the pre-application.
- If a clinical trial is proposed, the application will be withdrawn.
- The application fails to conform to this Program Announcement/Funding Opportunity description to the extent that appropriate review cannot be conducted
- The application describes research focusing on ALS. (Applications that focus on GWI symptomatology may include Gulf War Veterans with ALS if the latter disorder is included in the study's GWI case definition.)
- The application describes research whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI.
- An application submitted by a PI who does not meet the eligibility criteria will be withdrawn.

## **D. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to

provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

## **V. AWARD ADMINISTRATION INFORMATION**

### **A. Award Notice**

Awards will be made no later than September 30, 2016. Refer to the General Application Instructions, Appendix 3, for additional award administration information.

Any assistance instrument awarded under this Program Announcement/Funding Opportunity will be governed by the award terms and conditions, which conform to DoD's implementation of the Office of Management and Budget (OMB) circulars applicable to financial assistance. Terms and conditions of new awards made after December 26, 2014 may include revisions to reflect DoD implementation of new OMB guidance in the Code of Federal Regulations, Title 2, Part 200, "Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards" (2 CFR part 200).

### **B. Administrative Requirements**

Refer to the General Application Instructions, Appendix 3 for general information regarding administrative requirements.

### **C. National Policy Requirements**

Refer to the General Application Instructions, Appendix 4 for general information regarding national policy requirements.

### **D. Reporting**

Refer to the General Application Instructions, Appendix 3, Section I, for general information on reporting requirements.

Quarterly technical progress reports will be required.

### **E. Award Transfers**

Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

Refer to the General Application Instructions, Appendix 3, Section M, for general information on organization or PI changes.

## **VI. AGENCY CONTACTS**

### **A. CDMRP Help Desk**

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: [help@eBRAP.org](mailto:help@eBRAP.org)

### **B. Grants.gov Contact Center**

Questions related to application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726

Email: [support@grants.gov](mailto:support@grants.gov)

***Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.***

## VII. APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Upload Order	Action	Completed
SF-424 (R&R) Application for Federal Assistance		Complete form as instructed.	
Attachments Form	1	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf."	
	2	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf."	
	3	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf."	
	4	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf."	
	5	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf."	
	6	Impact Statement: Upload as Attachment 6 with file name "Impact.pdf."	
	7	Human Subject and Statistical Plan: Upload as Attachment 7 with file name "SubjectPlan.pdf."	
	8	Data Management Plan: Upload as Attachment 8 with file name "Data_Manage.pdf."	
	9	Surveys, Questionnaires, and Other Data Collection Instructions: Upload as Attachment 9 with file name "Surveys.pdf," if applicable.	
	10	Outcomes Statement : Upload as Attachment 10 with file name "Outcomes.pdf," if applicable	
	11	Collaborating DoD Military Facility Budget Form(s): Upload Attachment 11 with file name "MFBudget.pdf," if applicable.	
Research & Related Senior/Key Person Profile (Expanded)		Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
		Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.	
		Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
		Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.	
Research & Related Budget		Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form		Complete form as instructed.	
R & R Subaward Budget Attachment(s) Form		Complete form as instructed.	